-
Product Insights
Likelihood of Approval Analysis for Dementia
Overview How likely is it that the drugs in Dementia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dementia Overview Dementia is the decline in cognitive abilities that impacts a person's...
-
Product Insights
Likelihood of Approval Analysis for Dementia Associated With Alzheimer’s Disease
Overview How likely is it that the drugs in Dementia Associated With Alzheimer's Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dementia Associated With Alzheimer's Disease Overview Alzheimer's disease (AD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Censavudine in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Censavudine in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Censavudine in Frontotemporal Dementia (FTD) Drug Details: Censavudine (Festinavir, BMS-986001,OBP-601)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBFT-02 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBFT-02 in Frontotemporal Dementia (FTD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PBFT-02 in Frontotemporal Dementia (FTD) Drug Details: PBFT-02 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – It-hMSC in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - It-hMSC in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. It-hMSC in Dementia Associated With Alzheimer's Disease Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rivastigmine in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rivastigmine in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rivastigmine in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Deudextromethorphan Hydrobromide + Quinidine Sulfate) in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Deudextromethorphan Hydrobromide + Quinidine Sulfate) in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Deudextromethorphan Hydrobromide + Quinidine Sulfate)...
-
Product Insights
Vascular Dementias – Drugs In Development, 2023
Global Markets Direct’s, ‘Vascular Dementias - Drugs In Development, 2023’, provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lewy Body Dementia – Drugs In Development, 2023
Global Markets Direct’s, ‘Lewy Body Dementia - Drugs In Development, 2023’, provides an overview of the Lewy Body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy Body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...